Mer­ri­mack to dis­solve af­ter record­ing $225M mile­stone; Co­gen­t's $225M place­ment

Plus, news about Lari­mar Ther­a­peu­tics, Metageno­mi, Next­Point Ther­a­peu­tics, MeiraGTx, Codex­is, In­vi­tae, Im­munome and BioX­cel Ther­a­peu­tics:

Ipsen to pay $225M to Mer­ri­mack Phar­ma­ceu­ti­cals: The mile­stone pay­out was an­nounced the same day that Mer­ri­mack said it would seek to dis­solve the com­pa­ny. Ipsen in 2017 bought the US rights to Onivyde, which re­ceived an FDA la­bel ex­pan­sion in first-line metasta­t­ic pan­cre­at­ic can­cer, as part of a broad­er on­col­o­gy deal. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER